Unilabs announced today the two-year status on testing in Europe and several other markets outside Europe with the CE marked ELISA test STRATIFY JCV®. STRATIFY JCV is an important tool used to help enable individual benefit-risk assessment for patients with multiple sclerosis (MS) who are considering treatment with TYSABRI (natalizumab) by identifying their anti-JC virus (JCV) antibody status.

“In our two-year partnership with Unilabs, more than 80,000 samples from approximately 3,200 neurologists in 50 countries have been tested. This capacity coupled with their world-class service model and multi-lingual ordering process has helped make access to STRATIFY JCV as simple as possible for neurologists,” said Meena Subramanyam, Ph. D., Vice President, Translational Medicine at Biogen Idec.

Full Press Release